(Date:5/23/2013)... Just released this month on Amazon and ... Barbara Roche: “Commit to Confidence: 30 Strategies to Help ... tips and quotes from the fields of psychology and business, ... that readers can do on their own or with a ... and professional goals. , “My book is a ...
(Date:5/22/2013)... 2013 iLuv Creative Technology, the premier ... the mobile lifestyle, announces they are now shipping MultiCharger-X, ... multiple iPad devices efficiently. Winner of the 2013 internationally ... Design award, MultiCharger-X is revolutionizing the way businesses, schools, ... deployed. , MultiCharger-X (iAD910) combines the ...
(Date:5/22/2013)... NEW YORK , May 22, 2013 /PRNewswire/ ... pioneering the development of disease modifying therapeutics for ... today the completion of its Series B financing, ... shares and warrants that would represent approximately $2.8M ... investors and new investors supported the raise. ...
(Date:5/22/2013)... and NEW ORLEANS , ... in the field of regenerative medicine, presented new data ... from Analysis Group (a leading health economics consultancy) demonstrating ... foot ulcers (DFU) and venous leg ulcers (VLU) place ... results of this research, which reveal annual costs of ...
Breaking Biology Technology:iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4... 24 Cylene Pharmaceuticals, Inc. announced today the ... their first-in-class, oral CK2 inhibitor CX-4945 in patients ... closing of a $12 million financing with participation ... (Cayman) Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly ...
... N.J. and BRUSSELS, Sept. 24 Tarsa Therapeutics, ... UGNE ) today reported preclinical data ... combination with other drugs in reducing the collagen ... presented at the 2010 Osteoarthritis Research Society International ...
... the past 40 years describing the intricate series of ... two, they still haven,t agreed on how the process ... now may be reconciled by a third theory being ... could provide insights into the initiation of disease, such ...
Cached Biology Technology:Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing 2Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing 3Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis 2Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis 3Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis 4Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis 5Genetic switch underlies noisy cell division 2RAB32, member RAS oncogene family, mRNA (cDNA clone MGC:13500 IMAGE:4280407), complete cds...
APOPTAG® Plastic Coverslips are designed to be custom fitted to the specific APOPTAG® kit application. Each coverslip has 2.5 x 1 dimensions....
Recombinant Mouse TGF-beta RII/(human) Fc Chimera, CF...
Human Norrin Biotinylated Affinity Purified PAb Protein Family: Other Growth Factors, Other Wnt-related Molecules...
Biology Products:Biology NavigationMedical Navigation